|
|
Vaccine Detail
|
Plasmacytoid Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Plasmacytoid Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007097
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- IL13RA2
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- CLEC4C
gene engineering:
- NRP1
gene engineering:
- TLR9
gene engineering:
- TLR7
gene engineering:
- Preparation: When stimulated with IL-3, pDCs are shown to assume a cDC-like morphology, mature into antigen presenting cells and acquire the ability to stimulate TH2 responses (Mitchell et al., 2018).
- Description: This is for Melanoma Cancer (NCT01690377). A whole cell vaccine derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology that exhibits immunomodulating activity. Plasmacytoid dendritic cells (pDCs) express a characteristic set of surface markers, such as CD123 (interleukin-3 receptor alpha chain), BDCA-2 (blood dendritic cell antigen 2; CD303) and BDCA-4 (CD304), as well as intracellular toll-like receptors 7 and 9. Upon stimulation, the activated pDCs produce substantial amounts of interferon (IFN) alpha, and to a lesser degree IFN-beta, as well as other cytokines and chemokines, such as tumor necrosis factor alpha and interleukins 1, 6 and 8. In addition, these pDCs, directly or indirectly stimulate T-cells, B-cells and natural killer cells. This may potentially lead to increased immunity against tumor cells (Mitchell et al., 2018; NCIT_C103192).
|
| Host Response |
|
|
| References |
Mitchell et al., 2018: Mitchell D, Chintala S, Dey M. Plasmacytoid dendritic cell in immunity and cancer. Journal of neuroimmunology. 2018; 322; 63-73. [PubMed: 30049538].
NCIT_C103192: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C103192]
NCT01690377: [https://clinicaltrials.gov/ct2/show/NCT01690377]
|
|
